Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.4% – Time to Sell?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) traded down 4.4% on Wednesday . The company traded as low as $2.37 and last traded at $2.38. 955,137 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,482,567 shares. The stock had previously closed at $2.49.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The stock has a market capitalization of $609.36 million, a price-to-earnings ratio of -1.89 and a beta of 1.98. The business has a 50-day moving average of $3.55 and a 200-day moving average of $3.83.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) EPS. Equities analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC increased its stake in shares of Autolus Therapeutics by 853.2% during the second quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after buying an additional 169,387 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Autolus Therapeutics by 74.5% during the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after buying an additional 1,080,897 shares during the period. Privium Fund Management B.V. increased its stake in shares of Autolus Therapeutics by 220.9% during the second quarter. Privium Fund Management B.V. now owns 160,639 shares of the company’s stock worth $543,000 after buying an additional 110,581 shares during the period. Wealth Effects LLC increased its stake in shares of Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock worth $171,000 after buying an additional 8,000 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after purchasing an additional 15,293 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.